CHRNA7 and COVID-19: Given that α7 nAChR possesses anti-inflammatory properties and may interact with SARS-CoV-2 S protein, activating α7 nAChR-mediated cholinergic anti-inflammatory pathway might be an ideal therapeutic strategy for COVID-19.